Panel: Going Public in 2026: The New Biotech Playbook

Session details:

How biotech companies are navigating today’s IPO market   The rise of reverse mergers and SPACs as alternative routes to access public capital   What investors are looking for today—from valuation expectations to stage of entry   How capital is being recycled across the ecosystem and what that means for emerging biotech companies   Real-world insights on structuring deals and choosing the right path to go public in a shifting market